TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Stopped Study terminated for strategic business reasons
Conditions
Interventions
- DRUG: 400mg of TQB3909 tablets
- DRUG: 600mg of TQB3909 tablets
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.